XLOXilio Therapeutics, Inc.

$28M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$449,000

Operating Income

-$18M

Net Income

-$18M

EPS (Diluted)

$-0.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$61M

Total Liabilities

$24M

Stockholders' Equity

$37M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$449,000	$0	—
Operating Income	-$18M	-$23M	+21.7%
Net Income	-$18M	-$22M	+21.4%

XLO Q4 2023 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena